Mark Scholz, MD

Looking toward the future management of metastatic HSPC, experts consider the results of triplet combination trials like ARASENS and PEACE-1.

Expert perspectives on optimal genomic testing practices in patients with prostate cancer.

Discussion on the selection of therapy for a patient with metastatic HSPC in the context of available agents and FDA approvals.

Switching to a patient scenario of metastatic hormone-sensitive prostate cancer, experts discuss which therapeutic approach they would undertake.

A brief discussion on the role of PSMA-targeted therapy’s role in managing patients with nonmetastatic castration-resistant prostate cancer.

Shared insight on the selection of specific androgen receptor inhibitors for patients with nonmetastatic castration-resistant prostate cancer.

Centering the discussion around a patient with nonmetastatic castration-resistant prostate cancer, experts share insight on optimal work-up and testing.

Expert perspectives on the use of LHRH agonists versus antagonists in the management of prostate cancer.

A comprehensive overview on androgen-deprivation therapy in prostate cancer and the various therapeutic agents it consists of.